Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study

• Published in: Frontiers in immunology 2024-02, Vol.15, p.1332492-1332492
• Main Authors: Xie, Shu-Han, Yang, Li-Tao, Zhang, Hai, Tang, Zi-Lu, Lin, Zhi-Wei, Chen, Yi, Hong, Zhi-Nuan, Xu, Rong-Yu, Lin, Wan-Li, Kang, Ming-Qiang
• Format: Article
• Language: English
• Subjects: adjuvant therapy; Disease-Free Survival; esophageal cancer; Esophageal Neoplasms - pathology; Esophageal Squamous Cell Carcinoma - therapy; Humans; Immunology; neoadjuvant chemoimmunotherapy; Neoadjuvant Therapy; Propensity Score; propensity score matching; recurrence-free survival; Retrospective Studies
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1332492

The need for adjuvant therapy (AT) following neoadjuvant chemoimmunotherapy (nICT) and surgery in esophageal squamous cell cancer (ESCC) remains uncertain. This study aims to investigate whether AT offers additional benefits in terms of recurrence-free survival (RFS) for ESCC patients after nICT and surgery. Retrospective analysis was conducted between January 2019 and December 2022 from three centers. Eligible patients were divided into two groups: the AT group and the non-AT group. Survival analyses comparing different modalities of AT (including adjuvant chemotherapy and adjuvant chemoimmunotherapy) with non-AT were performed. The primary endpoint was RFS. Propensity score matching(PSM) was used to mitigate inter-group patient heterogeneity. Kaplan-Meier survival curves and Cox regression analysis were employed for recurrence-free survival analysis. A total of 155 nICT patients were included, with 26 patients experiencing recurrence. According to Cox analysis, receipt of adjuvant therapy emerged as an independent risk factor(HR:2.621, 95%CI:[1.089,6.310], P=0.032), and there was statistically significant difference in the Kaplan-Meier survival curves between non-AT and receipt of AT in matched pairs (p=0.026). Stratified analysis revealed AT bring no survival benefit to patients with pathological complete response(p= 0.149) and residual tumor cell(p=0.062). Subgroup analysis showed no significant difference in recurrence-free survival between non-AT and adjuvant chemoimmunotherapy patients(P=0.108). However, patients receiving adjuvant chemotherapy exhibited poorer recurrence survival compared to non-AT patients (p= 0.016). In terms of recurrence-free survival for ESCC patients after nICT and surgery, the necessity of adjuvant therapy especially the adjuvant chemotherapy, can be mitigated.